突变型Rad50腺病毒载体的制备及其在人鼻咽癌细胞株CNE1中的最适感染量测定

严睿成; 黄健聪; 朱玲; 常利红; 黎景佳; 吴喜福; 叶进; 张革化

doi:10.13201/j.issn.1001-1781.2015.24.010

突变型Rad50腺病毒载体的制备及其在人鼻咽癌细胞株CNE1中的最适感染量测定

- 1. 中山大学附属第三医院耳鼻咽喉头颈外科(广州, 510630);
- 2. 广州市增城区人民医院耳鼻咽喉科;
- 3. 广东省佛山市南海妇幼保健院耳鼻咽喉科
基金项目:
广东省对外合作项目(No:2012B050600015)

详细信息

通讯作者: 张革化,E-mail:gehuazh@hotmail.com

中图分类号: R739.63

收稿日期: 2015-09-01

The preparation of recombinant adenovirus Ad-Rad50-GFP and detection of the optimal multiplicity of infection in CNE1 transfected by Ad-Rad50-GFP

- 1 Department of Otolaryngology Head and Neck Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China;
- 2 Department of Otolaryngology, Nanhai Maternity and Child Healthcare Hospital

More Information

Corresponding author: ZHANG Gehua, E-mail: gehuazh@hotmail.com

Received Date: 01 September 2015

摘要

摘要: 目的: 测定携带突变型Rad50基因的重组腺病毒载体Ad-Rad50-GFP在人鼻咽癌细胞株CNE1中的表达及其对CNE1的最适感染倍率(MOI)。方法: 终点稀释法测定Ad-Rad50-GFP生物滴度,细胞生长曲线观察重组腺病毒载体对CNE1生长的影响,荧光显微镜下计算重组腺病毒载体的转染效率;免疫印迹实验检测以最适感染量感染后CNE1细胞内突变型Rad50蛋白的表达。结果: Ad-Rad50-GFP生物滴度为1.26×10¹¹ pfu/ml,重组腺病毒载体以不高于50的感染倍率转染时对CNE1生长无明显影响,且MOI=50时转染24 h后GFP表达水平最高,可检出高表达的突变型Rad50蛋白,在转染72 h后仍维持约70%的转染效率。结论: 重组腺病毒载体Ad-Rad50-GFP能有效转染CNE1细胞并使其表达突变型Rad50蛋白,MOI=50为Ad-Rad50-GFP 对CNE1的最适感染倍率。
- 重组腺病毒 /
- 鼻咽肿瘤 /
- 感染倍率
Abstract: Objective The optimal multiplicity of infection (MOI) of the recombinant adenovirus Ad-Rad50-GFP carrying a mutant Rad50 gene expression region on the cell growth of nasopharyngeal carcinoma and the viral amplification efficiency of CNE1 cell infected by this adenovirus were studied. Method: The biological titer of Ad-Rad50-GFP was measured by end point dilution method. The impact of recombinant adenoviral vector transfection on the growth of CNE1 cells was observed by cell growth curve. Transfection efficacy of recombinant adenoviral vector was observed and calculated through fluorescence microscope. The expression f mutant Rad50 in the Ad-Rad50-GFP transfected CNE1 cells with optimal MOI was detected by Western Blot after transfection.Result: The biological titer of Ad-Rad50-GFP was 1.26×10¹¹pfu/ml. CNE1 cell growth was not influenced significantly as they were transfected by recombinant adenoviral vector with MOI less than 50. Transfection efficacy of recombinant adenoviral vector was most salient at 24 hours after transfection, with the high expression of mutant Rad50, and the efficiency still remained about 70% after 72 hours. Conclusion: Recombinant adenoviral vector Ad-Rad50-GFP could transfect CNE1 cells as well as result in the expression of mutant Rad50 in CNE1 cells effectively. MOI=50 was the optimal multiplicity of infection of CNE1 cells transfected by recombinant adenoviral vector Ad-Rad50-GFP.
- recombinant adenoviral vector /
- nasopharyngeal neoplasms /
- multiplicity of infection

HTML全文

参考文献(10)

[1]	ZHANG Y,ZHOU J,LIM C U.The role of NBS1 in DNA double strand break repair,telomere stability,and cell cycle checkpoint control[J].Cell Res,2006,16:45-54.
[2]	STAVRIDI E S,HALAZONETIS T D.Nbs1 moving up in the world[J].Nat Cell Biol,2005,7:648-650.
[3]	CAO S M,SIMONS M J,QIAN C N.The prevalence and prevention of nasopharyngeal carcinoma in China[J].Chin J Cancer,2011,30:114-119.
[4]	SCHOTTENFELD D,FRAUMENI J F.Cancer epidemiology and prevention 3rd ed[M].New York:Oxford University Press,2006:620-626.
[5]	SHANMUGARATNAM K,SOBIN L H.The World Health Organization histological classification of tumours of the upper respiratory tract and ear.A commentary on the second edition[J].Cancer,1993,71:2689-2697.
[6]	ABUZEID W M,JIANG X,SHI G,et al.Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy[J].J Clin Invest,2009,119:1974-1985.
[7]	HUNG M C,HORTOBAGYI G N,UENO N T.Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer[J].Adv Exp Med Biol,2000,465:171-180.
[8]	FREYTAG S O,STRICKER H,PEGG J,et al.Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination withconventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed,intermediate-to high-risk prostate cancer[J].Cancer Res,2003,63:7497-7506.
[9]	FREYTAG S O,MOVSAS B,AREF I,et al.Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT forprostate cancer[J].Mol Ther,2007,15:1016-1023.
[10]	CHROBOCZEK J,BIEBER F,JACROT B.The sequence of the genome of adenovirus type 5and its comparison with the genome of adenovirus type 2[J].Virology,1992,186:280-285.